Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more
Molecure S.A. (MOC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.266x
Based on the latest financial reports, Molecure S.A. (MOC) has a cash flow conversion efficiency ratio of 0.266x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł26.15 Million) by net assets (zł98.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Molecure S.A. - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Molecure S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Molecure S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecure S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zero to Seven Inc
KQ:159580
|
0.002x |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-0.914x |
|
Cosmos Yatirim Holding AS
IS:COSMO
|
0.048x |
|
Themis Medicare Limited
NSE:THEMISMED
|
-0.004x |
|
West Coast Silver Ltd
AU:WCE
|
-3.405x |
|
Samebest Co Ltd
TWO:8489
|
-0.017x |
|
PJ Electronics Co. Ltd
KQ:006140
|
0.084x |
|
Nusasiri Public Company Limited
BK:NUSA
|
0.001x |
Annual Cash Flow Conversion Efficiency for Molecure S.A. (2015–2024)
The table below shows the annual cash flow conversion efficiency of Molecure S.A. from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł103.41 Million | zł-56.99 Million | -0.551x | -138.84% |
| 2023-12-31 | zł100.93 Million | zł-23.29 Million | -0.231x | -185.69% |
| 2022-12-31 | zł126.45 Million | zł-10.21 Million | -0.081x | +15.53% |
| 2021-12-31 | zł141.14 Million | zł-13.50 Million | -0.096x | -123.87% |
| 2020-12-31 | zł143.40 Million | zł57.44 Million | 0.401x | +545.88% |
| 2019-12-31 | zł79.13 Million | zł-7.11 Million | -0.090x | -50.45% |
| 2018-12-31 | zł81.89 Million | zł-4.89 Million | -0.060x | -195.95% |
| 2017-12-31 | zł29.72 Million | zł-599.63K | -0.020x | +81.79% |
| 2016-12-31 | zł13.01 Million | zł-1.44 Million | -0.111x | -11.67% |
| 2015-12-31 | zł15.43 Million | zł-1.53 Million | -0.099x | -- |